Clinical Trial Finder

Inclusion Criteria:

1. Unresectable or metastatic melanoma (Stages IIIC/IIID/IV per AJCC 8th edition) 2. Progressed on or did not achieve a response or were intolerant due to toxicity following 1-4 prior lines of systemic therapy including PD-1/ PD-L1 blocking antibody. 3. May have received adjuvant PD-1/PD-L1 blocking antibody if recurred within 6 months of discontinuation of therapy or while on therapy. 4. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL. 5. Must be ≥ 18 years of age at time of consent. 6. ECOG performance status of 0-1 and estimated life expectancy of ≥ 3 months. 7. Adequate hematologic parameters and organ function. 8. There is no alternative therapy.

Exclusion Criteria:

1. Received organ allograft, except kidney transplant, or prior cell transfer therapy including TIL and CAR-T therapies. 2. Ongoing grade 2-4 toxicity from prior immunotherapy (excluding endocrine, ocular toxicity or vitiligo) 3. Melanoma of uveal/ocular origin. 4. History of hypersensitivity to any component or excipient of lifileucel or other treatment regimen drugs. 5. Symptomatic and/or untreated brain metastases, unless definitively treated and stable for ≥ 14 days prior to beginning NMA LD preparative regimen. 6. Chronic systemic steroid therapy of > 10 mg/day. 7. Active medical illness(es) that would pose increased risk for protocol participation. 8. Must have negative syphilis assay and be seronegative for HIV, positive serology for HBV must have corresponding PCR assay and may be enrolled if viral load by PCR is undetectable. 9. Primary immunodeficiency. 10. Received live or attenuated vaccine within 28 days prior to beginning NMA-LD. 11. Pregnant or breastfeeding

Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process for the treatment of patients with advanced melanoma. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.